Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study

Publisher： Karger

E-ISSN： 1423-0232|91|3|127-134

ISSN： 0030-2414

Source： Oncology, Vol.91, Iss.3, 2016-07, pp. : 127-134

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prognostic Value of Pre- and Postoperative Anti-p53 Antibody Levels in Colorectal Cancer Patients: A Retrospective Study

By  

Oncology, Vol. 92, Iss. 1, 2016-10 ,pp. : 31-38

Karger

Access to resources Recommend Favorite

Relation between Serum Anti-p53 Antibodies and Microvessel Density in Bladder Cancer Patients

By  

Urologia Internationalis, Vol. 73, Iss. 3, 2004-11 ,pp. : 219-225

Karger

Access to resources Recommend Favorite

Anti-p53 in Breast Cancer: Concordance of Different Assay Procedures and Association with p53 Antigen Expression

By  

Oncology, Vol. 63, Iss. 3, 2002-10 ,pp. : 297-305

Karger

Access to resources Recommend Favorite

Efficacy and Safety of Irinotecan-Based Chemotherapy for Advanced Colorectal Cancer outside Clinical Trials: An Observational Study

By  

Oncology Research and Treatment, Vol. 33, Iss. 12, 2010-11 ,pp. : 684-690

Karger

Access to resources Recommend Favorite

Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study

By  

Oncology, Vol. 78, Iss. 5-6, 2010-08 ,pp. : 329-339

Karger

Access to resources Recommend Favorite